Claudin-1和HBME-1在甲状腺乳头状癌组织中的表达及临床意

刘玉兰，胡婕，陈金蓉，陈仕高Claudin-1和HBME-1在甲状腺乳头状癌组织中的表达及临床意义刘玉兰，胡婕，陈金蓉，陈仕高Claudin-1和HBME-1在甲状腺乳头状癌组织中的表达及临床意义-99-1材料与方法1.1一般资料1.2方法1.3统计学方法2结果2.1病灶组织中Claudin-1和HBME-1的表达2.2Claudin-1和HBME-1的表达情况与甲状腺乳头状癌一般特征的单因素分析2.3Claudin-1和HBME-1的表达相关性分析表1两组Claudin-1免疫组化结果比较组别n阳性阴性阳性率观察组99702970.7%对照组996936.5%表2两组HBME-1免疫组化结果比较组别n阳性阴性阳性率观察组99762376.8%对照组995945.3%ABCABC图APTC的HE染色结果HE40×图BClaudin-1阳性染色IHC40×图CHBME-1阳性染色IHC40×表3Claudin-1及HBME-1表达情况与甲状腺乳头状癌影响因素的单因素分析［ｎ（％）］影响因素nClaudin-1阳性c²PHBME-1阳性c²P性别男2314(0.607)1.40.23713(0.565)6.8860.009女7656(0.737)63(0.829)年龄（岁）>503018(0.600)2.3830.12322(0.733)0.2850.594≤506952(0.754)54(0.783)病灶大小（cm）>13026(0.867)5.2930.02129(0.967)9.5560.002≤16944(0.638)47(0.681)淋巴结转移有43(0.750)0.0370.8473(0.750)0.0070.932无9567(0.705)73(0.768)肿瘤数量（个）16645(0.682)0.610.43551(0.773)0.0280.866>13325(0.758)25(0.758)被膜侵犯是5949(0.831)10.7420.00154(0.915)17.832<0.001否4021(0.525)22(0.550)表4PTC组织中Claudin-1及HBME-1表达的相关性Claudin-1HBME-1r值P值阳性阴性阳性47230.2240.026阴性2903讨论参考文献MaiaFF,Zantut-WittmannDE.Thyroidnodulemanagement:clinical,ultrasoundandcytopathologicalparametersforpredictingmalignancy[J].Clinics,2012,67(8):945-954.ZhuX,YaoJ,TianW.Microarraytechnologytoinvestigategenesassociatedwithpapillarythyroidcarcinoma[J].MolMedRep,2015,11(5):3729-3733.RaposoL,MoraisS,OliveiraMJ,etal.TrendsinthyroidcancerincidenceandmortalityinPortugal[J].EurJCancerPrev,2016,26(2):135-143.BhatAA,SyedN,TherachiyilL,etal.Claudin-1,adouble-edgedswordincancer[J].IntJMolSci,2020,21,569.DuYL,LiangY,CaoY,etal.LncRNAXISTPromotesmigrationandinvasionofpapillarythyroidcancercellbymodulatingmiR-101-3p/CLDN1axis[J].BiochemGenet,2021,59(2):437-452.HasimotoY,OkadaY,ShirakuraK,etal.Anti-claudinantibodiesasaconceptfordevelopmentofclaudin-directeddrugs[J].PharmacolExpTher,2019,368(2):179-186.郭欣，吴志宇等.Claudin-1蛋白在甲状腺癌中的表达及调